Quick Takeaways
- Woodline Partners LP filed SCHEDULE 13G/A for Travere Therapeutics, Inc. Common Stock, par value $0.0001 per share (TVTX).
- Disclosed ownership: 2.4%.
- Date of event: 31 Dec 2024.
Woodline Partners LP - 31 Dec 2024 SCHEDULE 13G/A Report for Travere Therapeutics, Inc. Common Stock, par value $0.0001 per share (TVTX)
- Filing Manager
- Woodline Partners LP
- Reporting Manager
- Woodline Partners LP
- Symbol
- TVTX
- Shares outstanding
- 88,085,667 shares
- Disclosed Ownership
- 2,114,056 shares
- Ownership
- 2.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 16:06:34 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"Woodline Partners LP disclosed 2.4% ownership in Travere Therapeutics, Inc. Common Stock, par value $0.0001 per share (TVTX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 16:06.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Woodline Partners LP | 2.4% | 2,114,056 | 2,114,056 | 0 | /s/ Erin Mullen | Erin Mullen, General Counsel & Chief Compliance Officer |